A Danish pharmaceutical company is conducting extensive trials on a new drug aimed at weight loss and reducing obesity. The results have been astonishing, as it has not only succeeded in combating obesity but has also been shown to reduce the risk of death by 18%, making it potentially one of the most important drugs in the world. According to details published by the British newspaper "Financial Times," the new drug, named Wegovy, is produced by Novo Nordisk and has already proven effective in weight loss while significantly lowering mortality risk, based on the results from the studied sample.
The Danish pharmaceutical company hopes to convince more healthcare systems and insurance companies to cover the costs of this treatment, according to the newspaper. Martin Holst Lange, the executive vice president of development at Novo Nordisk, stated that the new data has demonstrated in greater detail how the drug is "incredibly powerful" in addressing cardiovascular disease risks. The new drug Wegovy is expensive, with monthly costs exceeding $1,300.
This information comes after initial results showed that patients taking Wegovy were 20% more prone to suffering from cardiovascular diseases such as stroke or heart attack compared to those receiving a placebo. Lange also mentioned that the trial showed the drug has effects on other conditions such as kidney diseases, stating, "I expect to see really interesting data on the drug's impact on chronic kidney diseases."
